보클로스포린[우산]

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

보클로스포린[우산] 화학적 특성, 용도, 생산

• 개요

  Voclosporin, a structurally similar analogue of cyclosporin A, is a new type of calcineurin inhibitor. It has been modified to increase its activity by 3-4 times and exhibits a dual and synergistic mechanism. This drug works by blocking the expression of IL-2 and T cell-mediated immune response, stabilizing renal podocytes. Compared to cyclosporin, voclosporin has the advantage of having less impact on cholesterol and triglycerides and a lower risk of diabetes. In February 2021, vorcyclosporine was approved by the FDA for use in combination immunosuppressive regimens in adult patients with active, lupus nephritis.

• 정의

  ChEBI: Voclosporin is a homodetic cyclic peptide. It is a semi-synthetic calcineurin (CN) inhibitor that exhibits potent immunosuppressive activity.

• Clinical Use

  Voclosporin (Lupkynis(TM)) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a background immunosuppressive therapy regimen for adults with active lupus nephritis.

• 참고 문헌

  1. Voclosporin: First Approval DOI: 10.1007/s40265-021-01488-z
  2. Voclosporin: A Novel Calcineurin Inhibitor for the Treatment of Lupus Nephritis DOI: 10.1177/10600280221075331

보클로스포린[우산] 공급 업체

Global(67)Suppliers